Banque Transatlantique SA Has $2.91 Million Position in Edwards Lifesciences Corporation $EW

Banque Transatlantique SA trimmed its position in Edwards Lifesciences Corporation (NYSE:EW) by 32.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,434 shares of the medical research company’s stock after selling 18,134 shares during the quarter. Banque Transatlantique SA’s holdings in Edwards Lifesciences were worth $2,907,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after buying an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after acquiring an additional 10,078 shares during the last quarter. Atlantic Union Bankshares Corp raised its position in Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock valued at $925,000 after purchasing an additional 11,384 shares in the last quarter. OMERS ADMINISTRATION Corp lifted its stake in Edwards Lifesciences by 97.3% during the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock worth $3,481,000 after purchasing an additional 21,950 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Down 3.3%

Shares of NYSE:EW opened at $81.82 on Friday. The firm has a market cap of $47.52 billion, a P/E ratio of 44.71, a P/E/G ratio of 2.21 and a beta of 0.93. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The business has a fifty day simple moving average of $82.41 and a 200 day simple moving average of $81.58. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences’s revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 24,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the sale, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 61,718 shares of company stock valued at $5,236,281 over the last quarter. Insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of a number of research analyst reports. BTIG Research reissued a “buy” rating and set a $103.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research note on Monday, January 12th. Citigroup reissued a “buy” rating and issued a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. TD Cowen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. Finally, JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.